Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2012

Open Access 01-06-2012 | NON-THEMATIC REVIEW

Cell–cell and cell–matrix dynamics in intraperitoneal cancer metastasis

Authors: Katharine L. Sodek, K. Joan Murphy, Theodore J. Brown, Maurice J. Ringuette

Published in: Cancer and Metastasis Reviews | Issue 1-2/2012

Login to get access

Abstract

The peritoneal metastatic route of cancer dissemination is shared by cancers of the ovary and gastrointestinal tract. Once initiated, peritoneal metastasis typically proceeds rapidly in a feed-forward manner. Several factors contribute to this efficient progression. In peritoneal metastasis, cancer cells exfoliate into the peritoneal fluid and spread locally, transported by peritoneal fluid. Inflammatory cytokines released by tumor and immune cells compromise the protective, anti-adhesive mesothelial cell layer that lines the peritoneal cavity, exposing the underlying extracellular matrix to which cancer cells readily attach. The peritoneum is further rendered receptive to metastatic implantation and growth by myofibroblastic cell behaviors also stimulated by inflammatory cytokines. Individual cancer cells suspended in peritoneal fluid can aggregate to form multicellular spheroids. This cellular arrangement imparts resistance to anoikis, apoptosis, and chemotherapeutics. Emerging evidence indicates that compact spheroid formation is preferentially accomplished by cancer cells with high invasive capacity and contractile behaviors. This review focuses on the pathological alterations to the peritoneum and the properties of cancer cells that in combination drive peritoneal metastasis.
Literature
1.
Lu, Z., Wang, J., Wientjes, M. G., & Au, J. L. (2010). Intraperitoneal therapy for peritoneal cancer. Future Oncology, 6(10), 1625–1641.PubMed
2.
Sadeghi, B., Arvieux, C., Glehen, O., Beaujard, A. C., Rivoire, M., Baulieux, J., et al. (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer, 88(2), 358–363.PubMed
3.
Finger, E. C., & Giaccia, A. J. (2010). Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer and Metastasis Reviews, 29(2), 285–293. doi:10.​1007/​s10555-010-9224-5 (Research support, N.I.H., Extramural review).PubMed
4.
Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research, 70(14), 5649–5669. doi:10.​1158/​0008-5472.​CAN-10-1040 (Research support, N.I.H., Extramural review).PubMed
5.
Karst, A. M., & Drapkin, R. (2010). Ovarian cancer pathogenesis: a model in evolution. Journal of Oncology, 2010, 932371.PubMed
6.
7.
Agarwal, R., & Kaye, S. B. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews. Cancer, 3(7), 502–516.PubMed
8.
Chien, J. R., Aletti, G., Bell, D. A., Keeney, G. L., Shridhar, V., & Hartmann, L. C. (2007). Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. Journal of Cellular Biochemistry, 102(5), 1117–1129.PubMed
9.
Kucukmetin, A., Naik, R., Galaal, K., Bryant, A., & Dickinson, H. O. (2010). Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database of Systematic Reviews, 7, CD007792.
10.
Stratton, J. F., Tidy, J. A., & Paterson, M. E. (2001). The surgical management of ovarian cancer. Cancer Treatment Reviews, 27(2), 111–118.PubMed
11.
Tan, D. S., Agarwal, R., & Kaye, S. B. (2006). Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet Oncology, 7(11), 925–934.PubMed
12.
Judson, P. L., Geller, M. A., Bliss, R. L., Boente, M. P., Downs, L. S., Jr., Argenta, P. A., et al. (2003). Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecologic Oncology, 91(2), 389–394.PubMed
13.
Koppe, M. J., Boerman, O. C., Oyen, W. J., & Bleichrodt, R. P. (2006). Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Annals of Surgery, 243(2), 212–222. doi:10.​1097/​01.​sla.​0000197702.​46394.​16 (Research support, non-U.S. government, Review).PubMed
14.
Ludeman, L., & Shepherd, N. A. (2005). Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology, 47(2), 123–131.PubMed
15.
Deraco, M., Baratti, D., Laterza, B., Balestra, M. R., Mingrone, E., Macri, A., et al. (2011). Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. European Journal of Surgical Oncology, 37(1), 4–9. doi:10.​1016/​j.​ejso.​2010.​11.​004 (Review).PubMed
16.
Harmon, R. L., & Sugarbaker, P. H. (2005). Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. International Seminars in Surgical Oncology, 2(1), 3. doi:10.​1186/​1477-7800-2-3.PubMed
17.
Tarin, D., Price, J. E., Kettlewell, M. G., Souter, R. G., Vass, A. C., & Crossley, B. (1984). Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Research, 44(8), 3584–3592.PubMed
18.
Eriksen, M. T., Wibe, A., Syse, A., Haffner, J., & Wiig, J. N. (2004). Inadvertent perforation during rectal cancer resection in Norway. British Journal of Surgery, 91(2), 210–216.PubMed
19.
Slanetz, C. A., Jr. (1984). The effect of inadvertent intraoperative perforation on survival and recurrence in colorectal cancer. Diseases of the Colon and Rectum, 27(12), 792–797.PubMed
20.
Fujiwara, Y., Doki, Y., Taniguchi, H., Sohma, I., Takiguchi, S., Miyata, H., et al. (2007). Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives. Gastric Cancer, 10(4), 197–204.PubMed
21.
Polyzos, N. P., Mauri, D., Tsioras, S., Messini, C. I., Valachis, A., & Messinis, I. E. (2010). Intraperitoneal dissemination of endometrial cancer cells after hysteroscopy: a systematic review and meta-analysis. International Journal of Gynecological Cancer, 20(2), 261–267.PubMed
22.
Ceelen, W. P., & Bracke, M. E. (2009). Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. The Lancet Oncology, 10(1), 72–79.PubMed
23.
Mutsaers, S. E. (2004). The mesothelial cell. The International Journal of Biochemistry & Cell Biology, 36(1), 9–16.
24.
Tingstedt, B., Isaksson, K., Andersson, E., & Andersson, R. (2007). Prevention of abdominal adhesions—present state and what's beyond the horizon? European Surgical Research, 39(5), 259–268.PubMed
25.
Mutsaers, S. E. (2002). Mesothelial cells: their structure, function and role in serosal repair. Respirology, 7(3), 171–191.PubMed
26.
Witz, C. A., Montoya-Rodriguez, I. A., Cho, S., Centonze, V. E., Bonewald, L. F., & Schenken, R. S. (2001). Composition of the extracellular matrix of the peritoneum. Journal of the Society for Gynecologic Investigation, 8(5), 299–304.PubMed
27.
Cui, L., Johkura, K., Liang, Y., Teng, R., Ogiwara, N., Okouchi, Y., et al. (2002). Biodefense function of omental milky spots through cell adhesion molecules and leukocyte proliferation. Cell and Tissue Research, 310(3), 321–330.PubMed
28.
Alkhamesi, N. A., Ziprin, P., Pfistermuller, K., Peck, D. H., & Darzi, A. W. (2005). ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clinical & Experimental Metastasis, 22(6), 449–459.
29.
Ksiazek, K., Mikula-Pietrasik, J., Catar, R., Dworacki, G., Winckiewicz, M., Frydrychowicz, M., et al. (2009). Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. International Journal of Cancer, 127(2), 293–303.
30.
Slack-Davis, J. K., Atkins, K. A., Harrer, C., Hershey, E. D., & Conaway, M. (2009). Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Research, 69(4), 1469–1476.PubMed
31.
Cannistra, S. A., Kansas, G. S., Niloff, J., DeFranzo, B., Kim, Y., & Ottensmeier, C. (1993). Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Research, 53(16), 3830–3838.PubMed
32.
Casey, R. C., & Skubitz, A. P. (2000). CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clinical & Experimental Metastasis, 18(1), 67–75.
33.
Lessan, K., Aguiar, D. J., Oegema, T., Siebenson, L., & Skubitz, A. P. (1999). CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. American Journal of Pathology, 154(5), 1525–1537.PubMed
34.
Nakashio, T., Narita, T., Akiyama, S., Kasai, Y., Fujiwara, M., Ito, K., et al. (1997). Adhesion of human gastric and pancreatic cancer cells to peritoneal mesothelial cells is mediated by CD44 and beta(1) integrin. International Journal of Oncology, 10(1), 183–188.PubMed
35.
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., et al. (2004). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. Journal of Biological Chemistry, 279(10), 9190–9198.PubMed
36.
Burleson, K. M., Casey, R. C., Skubitz, K. M., Pambuccian, S. E., Oegema, T. R., Jr., & Skubitz, A. P. (2004). Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecologic Oncology, 93(1), 170–181.PubMed
37.
Burleson, K. M., Hansen, L. K., & Skubitz, A. P. (2004). Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clinical & Experimental Metastasis, 21(8), 685–697.
38.
Casey, R. C., Burleson, K. M., Skubitz, K. M., Pambuccian, S. E., Oegema, T. R., Jr., Ruff, L. E., et al. (2001). Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. American Journal of Pathology, 159(6), 2071–2080.PubMed
39.
Strobel, T., & Cannistra, S. A. (1999). Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecologic Oncology, 73(3), 362–367.PubMed
40.
Moser, T. L., Pizzo, S. V., Bafetti, L. M., Fishman, D. A., & Stack, M. S. (1996). Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. International Journal of Cancer, 67(5), 695–701. doi:10.​1002/​(SICI)1097-0215(19960904)67:​5<695:​:​AID-IJC18>3.​0.​CO;2–4 (Research support, non-U.S. government research support, U.S. government, P.H.S.).
41.
Fishman, D. A., Kearns, A., Chilukuri, K., Bafetti, L. M., O'Toole, E. A., Georgacopoulos, J., et al. (1998). Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion & Metastasis, 18(1), 15–26 (Research support, non-U.S. government research support, U.S. government, P.H.S.).
42.
Ellerbroek, S. M., Wu, Y. I., Overall, C. M., & Stack, M. S. (2001). Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. Journal of Biological Chemistry, 276(27), 24833–24842. doi:10.​1074/​jbc.​M005631200 (Research support, U.S. government, non-P.H.S. research support, U.S. government, P.H.S.).PubMed
43.
Sodek, K. L., Evangelou, A. I., Ignatchenko, A., Agochiya, M., Brown, T. J., Ringuette, M. J., et al. (2008). Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Molecular BioSystems, 4(7), 762–773. doi:10.​1039/​b717542f (Research support, non-U.S. government research support, U.S. government, non-P.H.S.).PubMed
44.
Kawamura, T., Endo, Y., Yonemura, Y., Nojima, N., Fujita, H., Fujimura, T., et al. (2001). Significance of integrin alpha2/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. International Journal of Oncology, 18(4), 809–815.PubMed
45.
Bergstrom, M., Ivarsson, M. L., & Holmdahl, L. (2002). Peritoneal response to pneumoperitoneum and laparoscopic surgery. British Journal of Surgery, 89(11), 1465–1469 (Research support, non-U.S. government).PubMed
46.
Oosterling, S. J., van der Bij, G. J., van Egmond, M., & van der Sijp, J. R. (2005). Surgical trauma and peritoneal recurrence of colorectal carcinoma. European Journal of Surgical Oncology, 31(1), 29–37. doi:10.​1016/​j.​ejso.​2004.​10.​005 (Review).PubMed
47.
Mutsaers, S. E., & Wilkosz, S. (2007). Structure and function of mesothelial cells. Cancer Treatment and Research, 134, 1–19 (Review).PubMed
48.
Oosterling, S. J., van der Bij, G. J., Bogels, M., ten Raa, S., Post, J. A., Meijer, G. A., et al. (2008). Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Annals of Surgery, 247(1), 85–94. doi:10.​1097/​SLA.​0b013e3181588583​.PubMed
49.
Kenny, H. A., Krausz, T., Yamada, S. D., & Lengyel, E. (2007). Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. International Journal of Cancer, 121(7), 1463–1472. doi:10.​1002/​ijc.​22874 (Research support, N.I.H., extramural research support, non-U.S. government).
50.
Krist, L. F., Kerremans, M., Broekhuis-Fluitsma, D. M., Eestermans, I. L., Meyer, S., & Beelen, R. H. (1998). Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunology, Immunotherapy, 47(4), 205–212.PubMed
51.
Mochizuki, Y., Nakanishi, H., Kodera, Y., Ito, S., Yamamura, Y., Kato, T., et al. (2004). TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clinical & Experimental Metastasis, 21(1), 39–47 (Research support, non-U.S. government).
52.
Sorensen, E. W., Gerber, S. A., Sedlacek, A. L., Rybalko, V. Y., Chan, W. M., & Lord, E. M. (2012). Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunologic Research, 45(2–3), 185–194.
53.
Tsujimoto, H., Takhashi, T., Hagiwara, A., Shimotsuma, M., Sakakura, C., Osaki, K., et al. (1995). Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labelled cells. British Journal of Cancer, 71(3), 468–472.PubMed
54.
Oosterling, S. J., van der Bij, G. J., Bogels, M., van der Sijp, J. R., Beelen, R. H., Meijer, S., et al. (2006). Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease. Cancer Immunology, Immunotherapy, 55(9), 1043–1051. doi:10.​1007/​s00262-005-0101-y.PubMed
55.
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., et al. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature Medicine, 17(11), 1498–1503. doi:10.​1038/​nm.​2492.PubMed
56.
Kassis, J., Klominek, J., & Kohn, E. C. (2005). Tumor microenvironment: what can effusions teach us? Diagnostic Cytopathology, 33(5), 316–319. doi:10.​1002/​dc.​20280 (Review).PubMed
57.
Kulbe, H., Chakravarty, P., Leinster, D. A., Charles, K. A., Kwong, J., Thompson, R. G., et al. (2012). A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Research, 72, 66–75. doi:10.​1158/​0008-5472.​CAN-11-2178.PubMed
58.
Robinson-Smith, T. M., Isaacsohn, I., Mercer, C. A., Zhou, M., Van Rooijen, N., Husseinzadeh, N., et al. (2007). Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Research, 67(12), 5708–5716. doi:10.​1158/​0008-5472.​CAN-06-4375 (Research support, non-U.S. government).PubMed
59.
Freedman, R. S., Deavers, M., Liu, J., & Wang, E. (2004). Peritoneal inflammation—a microenvironment for epithelial ovarian cancer (EOC). Journal of Translational Medicine, 2(1), 23. doi:10.​1186/​1479-5876-2-23.PubMed
60.
Wang, E., Ngalame, Y., Panelli, M. C., Nguyen-Jackson, H., Deavers, M., Mueller, P., et al. (2005). Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clinical Cancer Research, 11(1), 113–122.PubMed
61.
Stadlmann, S., Raffeiner, R., Amberger, A., Margreiter, R., Zeimet, A. G., Abendstein, B., et al. (2003). Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha. Virchows Archiv, 443(5), 678–685. doi:10.​1007/​s00428-003-0867-2.PubMed
62.
63.
64.
Moradi, M. M., Carson, L. F., Weinberg, B., Haney, A. F., Twiggs, L. B., & Ramakrishnan, S. (1993). Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer, 72(8), 2433–2440 (Research support, non-U.S. government research support, U.S. government, P.H.S.).PubMed
65.
Zhang, X. Y., Pettengell, R., Nasiri, N., Kalia, V., Dalgleish, A. G., & Barton, D. P. (1999). Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. Journal of the Society for Gynecologic Investigation, 6(6), 333–340.PubMed
66.
Strobel, T., Swanson, L., & Cannistra, S. A. (1997). In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Research, 57(7), 1228–1232.PubMed
67.
Barni, S., Cabiddu, M., Ghilardi, M., & Petrelli, F. (2011). A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Critical Reviews in Oncology/Hematology, 79(2), 144–153. doi:10.​1016/​j.​critrevonc.​2010.​07.​016 (Review).PubMed
68.
Carmignani, C. P., Sugarbaker, T. A., Bromley, C. M., & Sugarbaker, P. H. (2003). Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer and Metastasis Reviews, 22(4), 465–472.PubMed
69.
Puls, L. E., Duniho, T., Hunter, J. E., Kryscio, R., Blackhurst, D., & Gallion, H. (1996). The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecologic Oncology, 61(1), 109–112.PubMed
70.
Ayantunde, A. A., & Parsons, S. L. (2007). Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Annals of Oncology, 18(5), 945–949. doi:10.​1093/​annonc/​mdl499 (Comparative study).PubMed
71.
72.
73.
74.
Stanovevik, Z., Rancic, G., Radic, S., Potic-Zecevic, N., Dordevic, B., & Todorvska, I. (2004). Pathogenesis of malignant ascites in ovarian cancer patients. Archive of Oncology, 12(2), 115–118.
75.
Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., et al. (1995). Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research, 55(2), 360–368 (Research support, non-U.S. government research support, U.S. government, P.H.S.).PubMed
76.
Melichar, B., & Freedman, R. S. (2002). Immunology of the peritoneal cavity: relevance for host–tumor relation. International Journal of Gynecological Cancer, 12(1), 3–17 (Research support, non-U.S. government, Review).PubMed
77.
Olson, T. A., Mohanraj, D., Carson, L. F., & Ramakrishnan, S. (1994). Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Research, 54(1), 276–280 (Research support, non-U.S. government research support, U.S. government, P.H.S.).PubMed
78.
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219(4587), 983–985 (Research support, non-U.S. government).PubMed
79.
Kobold, S., Hegewisch-Becker, S., Oechsle, K., Jordan, K., Bokemeyer, C., & Atanackovic, D. (2009). Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? The Oncologist, 14(12), 1242–1251. doi:10.​1634/​theoncologist.​2009-0109 (Research support, non-U.S. government, Review).PubMed
80.
Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L., et al. (2012). A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecologic Oncology, 125, 42–47. doi:10.​1016/​j.​ygyno.​2011.​11.​021.PubMed
81.
Gotlieb, W. H., Amant, F., Advani, S., Goswami, C., Hirte, H., Provencher, D., et al. (2012). Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Oncology, 13(2), 154–162. doi:10.​1016/​S1470-2045(11)70338-2 (Research support, non-U.S. government).PubMed
82.
Chen, X. L., Nam, J. O., Jean, C., Lawson, C., Walsh, C. T., Goka, E., et al. (2012). VEGF-induced vascular permeability is mediated by FAK. Developmental Cell, 22(1), 146–157. doi:10.​1016/​j.​devcel.​2011.​11.​002 (Research support, N.I.H., extramural research support, non-U.S. government).PubMed
83.
Wang, Y., Qu, Y., Niu, X. L., Sun, W. J., Zhang, X. L., & Li, L. Z. (2011). Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine, 56(2), 365–375. doi:10.​1016/​j.​cyto.​2011.​06.​005 (Research support, non-U.S. government).PubMed
84.
Lane, D., Matte, I., Rancourt, C., & Piche, A. (2011). Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer, 11, 210. doi:10.​1186/​1471-2407-11-210 (Research support, non-U.S. government).PubMed
85.
Baykal, C., Demirtas, E., Al, A., Ayhan, A., Yuce, K., Tulunay, G., et al. (2003). Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. International Journal of Gynecological Cancer, 13(6), 771–775 (Comparative study duplicate publication, research support, non-U.S. government).PubMed
86.
Miyamoto, S., Hirata, M., Yamazaki, A., Kageyama, T., Hasuwa, H., Mizushima, H., et al. (2004). Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Research, 64(16), 5720–5727. doi:10.​1158/​0008-5472.​CAN-04-0811 (Research support, non-U.S. government).PubMed
87.
Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X. J., Sharma, A., et al. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clinical Cancer Research, 1(10), 1223–1232 (Research support, non-U.S. government).PubMed
88.
Connor, J. P., & Felder, M. (2008). Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecologic Oncology, 111(2), 330–335. doi:10.​1016/​j.​ygyno.​2008.​07.​012.PubMed
89.
Lane, D., Goncharenko-Khaider, N., Rancourt, C., & Piche, A. (2010). Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene, 29(24), 3519–3531. doi:10.​1038/​onc.​2010.​107 (Research support, non-U.S. government).PubMed
90.
Puiffe, M. L., Le Page, C., Filali-Mouhim, A., Zietarska, M., Ouellet, V., Tonin, P. N., et al. (2007). Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia, 9(10), 820–829 (Research support, non-U.S. government).PubMed
91.
Nagy, J. A., Meyers, M. S., Masse, E. M., Herzberg, K. T., & Dvorak, H. F. (1995). Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Research, 55(2), 369–375 (Research support, non-U.S. government, Research support, U.S. government, P.H.S.).PubMed
92.
Ghosh, S., Wu, Y., & Stack, M. S. (2002). Ovarian cancer-associated proteinases. Cancer Treatment and Research, 107, 331–351 (Research support, non-U.S. government Research support, U.S. government, non-P.H.S. Research support, U.S. government, P.H.S. review).PubMed
93.
Stack, M. S., Ellerbroek, S. M., & Fishman, D. A. (1998). The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. International Journal of Oncology, 12(3), 569–576 (Review).PubMed
94.
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295(5564), 2387–2392. doi:10.​1126/​science.​1067100 (Research support, non-U.S. government Research support, U.S. government, P.H.S. review).PubMed
95.
Dorman, G., Cseh, S., Hajdu, I., Barna, L., Konya, D., Kupai, K., et al. (2010). Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs, 70(8), 949–964. doi:10.​2165/​11318390-000000000-00000 (Research support, non-U.S. government, Review).PubMed
96.
Hirte, H., Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., et al. (2006). A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecologic Oncology, 102(2), 300–308. doi:10.​1016/​j.​ygyno.​2005.​12.​020 (Clinical trial, phase III multicenter study randomized controlled trial).PubMed
97.
Hotary, K., Li, X. Y., Allen, E., Stevens, S. L., & Weiss, S. J. (2006). A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes & Development, 20(19), 2673–2686. doi:10.​1101/​gad.​1451806 (Research support, N.I.H., extramural).
98.
Sabeh, F., Shimizu-Hirota, R., & Weiss, S. J. (2009). Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited]. The Journal of Cell Biology, 185(1), 11–19. doi:10.​1083/​jcb.​200807195 (Research support, N.I.H., extramural research support, non-U.S. governmen).PubMed
99.
Overall, C. M., & Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews. Cancer, 2(9), 657–672. doi:10.​1038/​nrc884 (Research support, non-U.S. government, Review).PubMed
100.
Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer, 2(3), 161–174. doi:10.​1038/​nrc745 (Research support, non-U.S. government Research support, U.S. government, P.H.S. review).PubMed
101.
102.
Sodek, K. L., Ringuette, M. J., & Brown, T. J. (2007). MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. British Journal of Cancer, 97(3), 358–367. doi:10.​1038/​sj.​bjc.​6603863 (Research support, non-U.S. government).PubMed
103.
Shaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A., & Vanderhyden, B. C. (2004). Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Molecular Therapy, 10(6), 1032–1042. doi:10.​1016/​j.​ymthe.​2004.​08.​013 (Research support, non-U.S. government).PubMed
104.
Nonaka, T., Nishibashi, K., Itoh, Y., Yana, I., & Seiki, M. (2005). Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/matrix metalloproteinase-14 in vivo. Molecular Cancer Therapeutics, 4(8), 1157–1166. doi:10.​1158/​1535-7163.​MCT-05-0127 (Research support, non-U.S. government).PubMed
105.
Kenny, H. A., Kaur, S., Coussens, L. M., & Lengyel, E. (2008). The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. The Journal of Clinical Investigation, 118(4), 1367–1379. doi:10.​1172/​JCI33775 (Research support, N.I.H., extramural research support, non-U.S. government Research support, U.S. government, non-P.H.S.).PubMed
106.
Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., & Goldberg, G. I. (1995). Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. Journal of Biological Chemistry, 270(10), 5331–5338 (Comparative study, Research support, non-U.S. government, Research support, U.S. government, P.H.S.).PubMed
107.
Tanaka, Y., Miyamoto, S., Suzuki, S. O., Oki, E., Yagi, H., Sonoda, K., et al. (2005). Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clinical Cancer Research, 11(13), 4783–4792 (Comparative study Research support, non-U.S. government).PubMed
108.
Yagi, H., Yotsumoto, F., & Miyamoto, S. (2008). Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial–mesenchymal transition. Molecular Cancer Therapeutics, 7(10), 3441–3451. doi:10.​1158/​1535-7163.​MCT-08-0417 (Research support, non-U.S. government).PubMed
109.
Tsujioka, H., Yotsumoto, F., Hikita, S., Ueda, T., Kuroki, M., & Miyamoto, S. (2011). Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Current Opinion in Obstetrics and Gynecology, 23(1), 24–30. doi:10.​1097/​GCO.​0b013e3283409c91​ (Research support, non-U.S. government, Review).PubMed
110.
Koshikawa, N., Mizushima, H., Minegishi, T., Iwamoto, R., Mekada, E., & Seiki, M. (2010). Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Research, 70(14), 6093–6103. doi:10.​1158/​0008-5472.​CAN-10-0346 (Research support, non-U.S. government).PubMed
111.
Koshikawa, N., Mizushima, H., Minegishi, T., Eguchi, F., Yotsumoto, F., Nabeshima, K., et al. (2011). Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Science, 102(1), 111–116. doi:10.​1111/​j.​1349-7006.​2010.​01748.​x (Research support, non-U.S. government).PubMed
112.
Remacle, A. G., Shiryaev, S. A., Radichev, I. A., Rozanov, D. V., Stec, B., & Strongin, A. Y. (2011). Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases. Journal of Biological Chemistry, 286(23), 21002–21012. doi:10.​1074/​jbc.​M110.​200139 (Research support, N.I.H., extramural).PubMed
113.
Clark, K., Langeslag, M., Figdor, C. G., & van Leeuwen, F. N. (2007). Myosin II and mechanotransduction: a balancing act. Trends in Cell Biology, 17(4), 178–186. doi:10.​1016/​j.​tcb.​2007.​02.​002 (Research support, non-U.S. government, review).PubMed
114.
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell, 139(5), 891–906. doi:10.​1016/​j.​cell.​2009.​10.​027 (Research support, N.I.H., Extramural, Research support, U.S. government, non-P.H.S.).PubMed
115.
116.
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., et al. (2005). Tensional homeostasis and the malignant phenotype. Cancer Cell, 8(3), 241–254. doi:10.​1016/​j.​ccr.​2005.​08.​010 (Research support, N.I.H., Extramural Research support, U.S. government, non-P.H.S., Research support, U.S. government, P.H.S.).PubMed
117.
Samuel, M. S., Lopez, J. I., McGhee, E. J., Croft, D. R., Strachan, D., Timpson, P., et al. (2011). Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell, 19(6), 776–791. doi:10.​1016/​j.​ccr.​2011.​05.​008 (Research support, non-U.S. government).PubMed
118.
de Rooij, J., Kerstens, A., Danuser, G., Schwartz, M. A., & Waterman-Storer, C. M. (2005). Integrin-dependent actomyosin contraction regulates epithelial cell scattering. The Journal of Cell Biology, 171(1), 153–164. doi:10.​1083/​jcb.​200506152 (Research support, N.I.H., Extramural Research support, non-U.S. government, Research support, U.S. government, P.H.S.).PubMed
119.
Wyckoff, J. B., Pinner, S. E., Gschmeissner, S., Condeelis, J. S., & Sahai, E. (2006). ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Current Biology, 16(15), 1515–1523. doi:10.​1016/​j.​cub.​2006.​05.​065 (Comparative study, Research support, N.I.H., Extramural Research support, non-U.S. government).PubMed
120.
Yamaguchi, H., Wyckoff, J., & Condeelis, J. (2005). Cell migration in tumors. Current Opinion in Cell Biology, 17(5), 559–564. doi:10.​1016/​j.​ceb.​2005.​08.​002 (Research support, N.I.H., Extramural, Research support, U.S. government, P.H.S. review).PubMed
121.
Provenzano, P. P., Eliceiri, K. W., Campbell, J. M., Inman, D. R., White, J. G., & Keely, P. J. (2006). Collagen reorganization at the tumor–stromal interface facilitates local invasion. BMC Medicine, 4(1), 38. doi:10.​1186/​1741-7015-4-38 (Research support, N.I.H., Extramural Research support, U.S. government, non-P.H.S.).PubMed
122.
Sodek, K. L., Ringuette, M. J., & Brown, T. J. (2009). Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. International Journal of Cancer, 124(9), 2060–2070. doi:10.​1002/​ijc.​24188 (Research support, non-U.S. government).
123.
Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., et al. (2007). Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nature Cell Biology, 9(12), 1392–1400. doi:10.​1038/​ncb1658 (Research support, non-U.S. government).PubMed
124.
Nash, M. A., Deavers, M. T., & Freedman, R. S. (2002). The expression of decorin in human ovarian tumors. Clinical Cancer Research, 8(6), 1754–1760.PubMed
125.
Yao, Q., Qu, X., Yang, Q., Wei, M., & Kong, B. (2009). CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer. Oncology Reports, 22(3), 541–548 (Research support, non-U.S. government).PubMed
126.
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008). Stromal myofibroblasts are drivers of invasive cancer growth. International Journal of Cancer, 123(10), 2229–2238. doi:10.​1002/​ijc.​23925 (Research support, non-U.S. government, Review).
127.
Desmouliere, A., Guyot, C., & Gabbiani, G. (2004). The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. International Journal of Developmental Biology, 48(5–6), 509–517. doi:10.​1387/​ijdb.​041802ad (Review).PubMed
128.
Suh, K. S., Crutchley, J. M., Koochek, A., Ryscavage, A., Bhat, K., Tanaka, T., et al. (2007). Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers. Clinical Cancer Research, 13(1), 121–131. doi:10.​1158/​1078-0432.​CCR-06-1562 (Research support, N.I.H., Intramural).PubMed
129.
Yao, Q., Cao, S., Li, C., Mengesha, A., Kong, B., & Wei, M. (2011). Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor–stroma interaction. International Journal of Cancer, 128(1792), 1783. doi:10.​1002/​ijc.​25506 (Research support, non-U.S. government).
130.
Aroeira, L. S., Aguilera, A., Sanchez-Tomero, J. A., Bajo, M. A., del Peso, G., Jimenez-Heffernan, J. A., et al. (2007). Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. Journal of the American Society of Nephrology, 18(7), 2004–2013. doi:10.​1681/​ASN.​2006111292 (Research support, non-U.S. government, Review).PubMed
131.
Loureiro, J., Aguilera, A., Selgas, R., Sandoval, P., Albar-Vizcaino, P., Perez-Lozano, M. L., et al. (2011). Blocking TGF-beta1 protects the peritoneal membrane from dialysate-induced damage. Journal of the American Society of Nephrology, 22(9), 1682–1695. doi:10.​1681/​ASN.​2010111197 (Research support, non-U.S. government).PubMed
132.
Lee, E. S., Leong, A. S., Kim, Y. S., Lee, J. H., Kim, I., Ahn, G. H., et al. (2006). Calretinin, CD34, and alpha-smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary. Modern Pathology, 19(3), 364–372. doi:10.​1038/​modpathol.​3800539.PubMed
133.
Radisky, D. C., Kenny, P. A., & Bissell, M. J. (2007). Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? Journal of Cellular Biochemistry, 101(4), 830–839. doi:10.​1002/​jcb.​21186 (Research support, N.I.H., Extramural, Research support, non-U.S. government, Research support, U.S. government, non-P.H.S., Review).PubMed
134.
Desoize, B., & Jardillier, J. (2000). Multicellular resistance: a paradigm for clinical resistance? Critical Reviews in Oncology/Hematology, 36(2–3), 193–207 (Research support, non-U.S. government, Review).PubMed
135.
Santini, M. T., Rainaldi, G., & Indovina, P. L. (2000). Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Critical Reviews in Oncology/Hematology, 36(2–3), 75–87 (Review).PubMed
136.
Allen, H. J., Porter, C., Gamarra, M., Piver, M. S., & Johnson, E. A. (1987). Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Experimental Cell Biology, 55(4), 194–208 (Research support, non-U.S. government, Research support, U.S. government, P.H.S.).PubMed
137.
Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003). Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnology and Bioengineering, 83(2), 173–180. doi:10.​1002/​bit.​10655 (Research support, non-U.S. government).PubMed
138.
Winters, B. S., Shepard, S. R., & Foty, R. A. (2005). Biophysical measurement of brain tumor cohesion. International Journal of Cancer, 114(3), 371–379. doi:10.​1002/​ijc.​20722 (Research support, non-U.S. government).
139.
Ahmed, N., Thompson, E. W., & Quinn, M. A. (2007). Epithelial–mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. Journal of Cellular Physiology, 213(3), 581–588. doi:10.​1002/​jcp.​21240 (Research support, non-U.S. government, Review).PubMed
140.
Ivascu, A., & Kubbies, M. (2007). Diversity of cell-mediated adhesions in breast cancer spheroids. International Journal of Oncology, 31(6), 1403–1413.PubMed
141.
Lin, R. Z., Chou, L. F., Chien, C. C., & Chang, H. Y. (2006). Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and beta1-integrin. Cell and Tissue Research, 324(3), 411–422. doi:10.​1007/​s00441-005-0148-2 (Research support, non-U.S. government).PubMed
142.
Robinson, E. E., Foty, R. A., & Corbett, S. A. (2004). Fibronectin matrix assembly regulates alpha5beta1-mediated cell cohesion. Molecular Biology of the Cell, 15(3), 973–981. doi:10.​1091/​mbc.​E03-07-0528.PubMed
143.
Robinson, E. E., Zazzali, K. M., Corbett, S. A., & Foty, R. A. (2003). Alpha5beta1 integrin mediates strong tissue cohesion. Journal of Cell Science, 116(Pt 2), 377–386.PubMed
144.
Shimazui, T., Schalken, J. A., Kawai, K., Kawamoto, R., van Bockhoven, A., Oosterwijk, E., et al. (2004). Role of complex cadherins in cell–cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. Oncology Reports, 11(2), 357–360.PubMed
145.
Dean, D. M., & Morgan, J. R. (2008). Cytoskeletal-mediated tension modulates the directed self-assembly of microtissues. Tissue Engineering. Part A, 14(12), 1989–1997. doi:10.​1089/​ten.​tea.​2007.​0320 (Research support, non-U.S. government, Research support, U.S. government, non-P.H.S.).PubMed
146.
Kohn, E. C., Travers, L. A., Kassis, J., Broome, U., & Klominek, J. (2005). Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagnostic Cytopathology, 33(5), 300–308. doi:10.​1002/​dc.​20279.PubMed
147.
Iwabu, A., Smith, K., Allen, F. D., Lauffenburger, D. A., & Wells, A. (2004). Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C delta-dependent pathway. Journal of Biological Chemistry, 279(15), 14551–14560. doi:10.​1074/​jbc.​M311981200 (Research support, U.S. government, P.H.S.).PubMed
148.
Kobayashi, T., Liu, X., Wen, F. Q., Kohyama, T., Shen, L., Wang, X. Q., et al. (2006). Smad3 mediates TGF-beta1-induced collagen gel contraction by human lung fibroblasts. Biochemical and Biophysical Research Communications, 339(1), 290–295. doi:10.​1016/​j.​bbrc.​2005.​10.​209 (Research support, N.I.H., Extramural).PubMed
149.
Lee, D. J., Ho, C. H., & Grinnell, F. (2003). LPA-stimulated fibroblast contraction of floating collagen matrices does not require Rho kinase activity or retraction of fibroblast extensions. Experimental Cell Research, 289(1), 86–94 (Research support, U.S. government, P.H.S.).PubMed
150.
Heldin, C. H., Rubin, K., Pietras, K., & Ostman, A. (2004). High interstitial fluid pressure—an obstacle in cancer therapy. Nature Reviews. Cancer, 4(10), 806–813. doi:10.​1038/​nrc1456 (Research support, non-U.S. government, Review).PubMed
151.
Dubessy, C., Merlin, J. M., Marchal, C., & Guillemin, F. (2000). Spheroids in radiobiology and photodynamic therapy. Critical Reviews in Oncology/Hematology, 36(2–3), 179–192 (Research support, non-U.S. government, Review).PubMed
152.
Xing, H., Wang, S., Hu, K., Tao, W., Li, J., Gao, Q., et al. (2005). Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. Journal of Cancer Research and Clinical Oncology, 131(8), 511–519. doi:10.​1007/​s00432-005-0677-9 (Research support, non-U.S. government).PubMed
153.
Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A., & Kerbel, R. S. (1993). Acquired multicellular-mediated resistance to alkylating agents in cancer. Proceedings of the National Academy of Sciences of the United States of America, 90(8), 3294–3298 (Research support, non-U.S. government, Research support, U.S. government, P.H.S.).PubMed
154.
Bookman, M. A. (2003). Developmental chemotherapy and management of recurrent ovarian cancer. Journal of Clinical Oncology, 21(10 Suppl), 149s–167s.PubMed
155.
Olson, M. F. (2008). Applications for ROCK kinase inhibition. Current Opinion in Cell Biology, 20(2), 242–248. doi:10.​1016/​j.​ceb.​2008.​01.​002 (Research support, N.I.H., Extramural, Research support, non-U.S. government, Review).PubMed
156.
157.
Zhang, H., Liu, X., Liu, Y., Yi, B., & Yu, X. (2011). Epithelial–mesenchymal transition of rat peritoneal mesothelial cells via Rhoa/Rock pathway. In Vitro Cellular and Developmental Biology—Animal, 47(2), 165–172. doi:10.​1007/​s11626-010-9369-0.PubMed
158.
Washida, N., Wakino, S., Tonozuka, Y., Homma, K., Tokuyama, H., Hara, Y., et al. (2011). Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrology, Dialysis, Transplantation, 26(9), 2770–2779. doi:10.​1093/​ndt/​gfr012 (Research support, non-U.S. government).PubMed
159.
Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., et al. (2007). A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nature Biotechnology, 25(6), 681–686. doi:10.​1038/​nbt1310 (Research support, non-U.S. government).PubMed
160.
Zhang, L., Valdez, J. M., Zhang, B., Wei, L., Chang, J., & Xin, L. (2011). ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One, 6(3), e18271. doi:10.​1371/​journal.​pone.​0018271 (Research support, N.I.H., Extramural, Research support, non-U.S. government).PubMed
161.
Pedersen, J. A., & Swartz, M. A. (2005). Mechanobiology in the third dimension. Annals of Biomedical Engineering, 33(11), 1469–1490. doi:10.​1007/​s10439-005-8159-4 (Research support, N.I.H., Extramural, Research support, non-U.S. government, Research support, U.S. government, non-P.H.S., Review).PubMed
162.
163.
Sabeh, F., Ota, I., Holmbeck, K., Birkedal-Hansen, H., Soloway, P., Balbin, M., et al. (2004). Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. The Journal of Cell Biology, 167(4), 769–781. doi:10.​1083/​jcb.​200408028 (Research support, U.S. government, P.H.S.).PubMed
164.
Sodek, K. L., Brown, T. J., & Ringuette, M. J. (2008). Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer, 8, 223. doi:10.​1186/​1471-2407-8-223 (Research support, non-U.S. government).PubMed
165.
Noel, A. C., Calle, A., Emonard, H. P., Nusgens, B. V., Simar, L., Foidart, J., et al. (1991). Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. Cancer Research, 51(1), 405–414 (In vitro, Research support, non-U.S. government).PubMed
166.
Engler, A. J., Sen, S., Sweeney, H. L., & Discher, D. E. (2006). Matrix elasticity directs stem cell lineage specification. Cell, 126(4), 677–689. doi:10.​1016/​j.​cell.​2006.​06.​044 (Research support, non-U.S. government, Research support, U.S. government, non-P.H.S.).PubMed
167.
168.
Ogura, T., Kobayashi, H., Ueoka, Y., Okugawa, K., Kato, K., Hirakawa, T., et al. (2006). Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells. Clinical Cancer Research, 12(17), 5216–5223. doi:10.​1158/​1078-0432.​CCR-06-0674 (Research support, non-U.S. government).PubMed
169.
Taniguchi, S. (2005). Suppression of cancer phenotypes through a multifunctional actin-binding protein, calponin, that attacks cancer cells and simultaneously protects the host from invasion. Cancer Science, 96(11), 738–746. doi:10.​1111/​j.​1349-7006.​2005.​00118.​x (Research support, non-U.S. government, Review).PubMed
Metadata
Title
Cell–cell and cell–matrix dynamics in intraperitoneal cancer metastasis
Authors
Katharine L. Sodek
K. Joan Murphy
Theodore J. Brown
Maurice J. Ringuette
Publication date
01-06-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9351-2

Other articles of this Issue 1-2/2012

Cancer and Metastasis Reviews 1-2/2012 Go to the issue

NON-THEMATIC REVIEW

In vivo animal models of spinal metastasis

NON-THEMATIC REVIEW

Biological influence of Hakai in cancer: a 10-year review

NON-THEMATIC REVIEW

Regulation of p53 by ING family members in suppression of tumor initiation and progression

NON-THEMATIC REVIEW

EMT in carcinoma progression and dissemination: Facts, unanswered questions, and clinical considerations

NON-THEMATIC REVIEW

The Eph/Ephrin family in cancer metastasis: communication at the service of invasion

NON-THEMATIC REVIEW

Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits